PRECEDE: A Global Effort to Increase Screening for High-Risk Pancreatic Cancer
By Adeline Cuggia, MSc, CCGC - Last Updated: March 19, 2025Adeline Cuggia, MSc, CCGC, genetic counselor and research coordinator at McGill University Health Centre in Montreal, discusses new findings of The Pancreatic Cancer Early Detection (PRECEDE) Consortium.
Advertisement
PRECEDE offers testing for individuals at high risk of pancreatic cancer, with multiple testing sites offered throughout North America and Europe.
Cuggia gives an overview of the barriers between screening and diagnosis, as well as plans to offer more testing sites.
Advertisement
Related Posts
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.